Get the Stockscreener App
14.63
4.07%
-0.62
After Hours:
14.73
0.10
+0.68%
Summit Therapeutics Inc stock is traded at $14.63, with a volume of 2.29M.
It is down -4.07% in the last 24 hours and down -14.14% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$15.25
Open:
$15.31
24h Volume:
2.29M
Relative Volume:
0.87
Market Cap:
$10.89B
Revenue:
$220.00K
Net Income/Loss:
$-921.61M
P/E Ratio:
-11.78
EPS:
-1.2418
Net Cash Flow:
$-274.60M
1W Performance:
+5.63%
1M Performance:
-14.14%
6M Performance:
-43.04%
1Y Performance:
-25.24%
1-Day Range:
$14.58
$15.38
1-Week Range:
$14.04
$15.77
52-Week Range:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
14.63 | 11.35B | 220.00K | -921.61M | -274.60M | -1.2418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Finviz
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data - MSN
Summit Therapeutics Insiders Placed Bullish Bets Worth US$275.0m - 富途牛牛
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date - simplywall.st
Is Summit Therapeutics Inc. stock a good pick for beginnersMarket Activity Report & Risk Controlled Daily Plans - baoquankhu1.vn
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential - Sahm
First Week of February 20th Options Trading For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance
Technical Reactions to SMMT Trends in Macro Strategies - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Merger Talk: Is Summit Therapeutics Inc impacted by rising rates2025 Buyback Activity & Fast Moving Stock Trade Plans - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Reaches New 12-Month LowShould You Sell? - MarketBeat
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer - MSN
Summit Therapeutics (SMMT) Stock Analysis: A Potential 128% Upside In Biotech - DirectorsTalk Interviews
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock - Investing.com
Summit Therapeutics (SMMT) Analyst Ratings Reaffirmed at Buy | S - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 30, 2026 - BioSpace
Encouraging guidance on clinical program makes Summit Therapeutics (SMMT) look attractive - MSN
2 Stocks That Could Soar This Year - The Globe and Mail
Summit spikes as lead asset undergoes FDA review - MSN
Yong Rong HK Asset Management Ltd Invests $2.07 Million in Summit Therapeutics PLC $SMMT - MarketBeat
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
Summit Therapeutics (SMMT) Analyst Rating Update: January 30, 20 - GuruFocus
Summit Therapeutics' (SMMT) Market Outperform Rating Reiterated at Citizens Jmp - MarketBeat
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA - Investing.com
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA By Investing.com - Investing.com Canada
US regulator accepts Summit filing for ivonescimab combo - The Pharma Letter
Summit Therapeutics (SMMT) Valuation Check After Recent Share Price Pullback And Conflicting Model Signals - Yahoo Finance
FDA Accepts Summit Therapeutics' BLA for Ivonescimab - intellectia.ai
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Aug Gainers: Is Summit Therapeutics Inc impacted by rising rates2025 Risk Factors & Growth Focused Stock Reports - baoquankhu1.vn
Summit Therapeutics (SMMT) Advances with FDA Filing for Cancer T - GuruFocus
Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab - marketscreener.com
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr - GuruFocus
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA - TipRanks
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug By Investing.com - Investing.com South Africa
Summit spikes as lead asset gets FDA review (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug - Investing.com Nigeria
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment - TradingView
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab - StreetInsider
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire
Summit Therapeutics (NASDAQ:SMMT) Sets New 12-Month LowHere's What Happened - MarketBeat
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive - Finviz
Exelixis and Summit Therapeutics: Future Prospects - Intellectia AI
Aug Retail: Can Summit Therapeutics Inc be the next market leaderPortfolio Risk Summary & Fast Moving Market Watchlists - baoquankhu1.vn
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):